Deutsche Bank AG Purchases 71,421 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Deutsche Bank AG increased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 42.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 240,744 shares of the company’s stock after acquiring an additional 71,421 shares during the period. Deutsche Bank AG owned about 0.49% of Mirum Pharmaceuticals worth $10,846,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Summit Investment Advisors Inc. grew its position in Mirum Pharmaceuticals by 8.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company’s stock worth $172,000 after acquiring an additional 312 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in shares of Mirum Pharmaceuticals by 2.1% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 16,685 shares of the company’s stock valued at $752,000 after buying an additional 339 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Mirum Pharmaceuticals by 3.8% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,998 shares of the company’s stock valued at $495,000 after buying an additional 398 shares during the last quarter. CWM LLC grew its position in shares of Mirum Pharmaceuticals by 259.4% in the 1st quarter. CWM LLC now owns 593 shares of the company’s stock valued at $27,000 after buying an additional 428 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its position in shares of Mirum Pharmaceuticals by 2.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 17,200 shares of the company’s stock valued at $711,000 after buying an additional 487 shares during the last quarter.

Insider Buying and Selling

In related news, SVP Jolanda Howe sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $58.00, for a total transaction of $580,000.00. Following the transaction, the senior vice president directly owned 2,426 shares of the company’s stock, valued at approximately $140,708. This represents a 80.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Peetz sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $62.00, for a total value of $2,480,000.00. Following the transaction, the chief executive officer directly owned 138,641 shares in the company, valued at approximately $8,595,742. This trade represents a 22.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 91,041 shares of company stock worth $5,320,624. 14.36% of the stock is owned by company insiders.

Mirum Pharmaceuticals Stock Down 0.5%

MIRM stock opened at $64.83 on Friday. The stock’s 50 day simple moving average is $52.46 and its 200 day simple moving average is $47.66. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.86 and a fifty-two week high of $67.45. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.97 and a current ratio of 3.13. The company has a market cap of $3.26 billion, a P/E ratio of -53.58 and a beta of 0.94.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative return on equity of 24.76% and a negative net margin of 13.65%. The business had revenue of $127.79 million for the quarter, compared to the consensus estimate of $107.91 million. During the same period in the prior year, the business earned ($0.52) EPS. The firm’s revenue for the quarter was up 64.1% on a year-over-year basis. On average, research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MIRM has been the topic of a number of analyst reports. JMP Securities set a $81.00 price target on Mirum Pharmaceuticals and gave the company a “market outperform” rating in a research report on Thursday, August 7th. Evercore ISI upped their price target on Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. HC Wainwright upped their price target on Mirum Pharmaceuticals from $73.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, August 7th. Raymond James Financial reiterated a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded Mirum Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $74.13.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.